| Market Capitalization (Millions $) |
530 |
| Shares
Outstanding (Millions) |
99 |
| Employees |
208 |
| Revenues (TTM) (Millions $) |
106 |
| Net Income (TTM) (Millions $) |
-173 |
| Cash Flow (TTM) (Millions $) |
-49 |
| Capital Exp. (TTM) (Millions $) |
13 |
Fate Therapeutics Inc
Fate Therapeutics Inc is a biopharmaceutical company that develops advanced cellular therapies that can replace or repair damaged cells in people suffering from severe diseases.
The company is based in San Diego, California, and was founded in 2007.
The company's innovative approach to therapy involves taking cells from a patient's body, engineering them to become specific types of cells, and then reintroducing them into the patient's body, where they can replace or repair damaged cells.
This approach offers a potential solution to many severe diseases, including cancer, genetic disorders, and autoimmune diseases.
Fate Therapeutics Inc's main product is FT516, a treatment designed to replace natural killer cells that work to identify and destroy cancer cells in the body with healthy cells produced outside the body.
They also have other products in development, including FT500, a cancer-killing cell therapy, and FT819, a CAR T-cell therapy for B-cell malignancies.
The company has a strong focus on research and development, and they have partnerships with many leading medical and academic institutions worldwide.
They have also established a strong intellectual property portfolio, which includes over 300 patents and patent applications in the field of cellular therapy.
In summary, Fate Therapeutics Inc is a cutting-edge biopharmaceutical company that develops advanced cellular therapies that can provide a potential cure for many severe diseases.
They have a strong focus on research, development, and intellectual property, making them a leader in the field of cellular therapy.
Company Address: 12278 Scripps Summit Drive San Diego 92131 CA
Company Phone Number: 875-1800 Stock Exchange / Ticker: NASDAQ FATE
|
